PTEN blocks insulin-mediated ETS-2 phosphorylation through MAP kinase, independently of the phosphoinositide 3-kinase pathway

Human Molecular Genetics

Volumn 11, Issue 15, 2002, Pages 1687-1696

  Weng, Liang Ping ^a,b,c   Brown, Jessica L ^a,c   Baker, Kim M ^a,c   Ostrowski, Michael C ^a,c   Eng, Charis ^a,b,c,d  

^a OHIO STATE UNIVERSITY   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR; INSULIN; LIPID; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHOPROTEIN PHOSPHATASE; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN KINASE B; RAS PROTEIN; SOMATOMEDIN C; TRANSCRIPTION FACTOR ETS 2; DNA BINDING PROTEIN; ERF PROTEIN, HUMAN; ETS2 PROTEIN, HUMAN; GROWTH PROMOTOR; HYPERGLYCEMIC AGENT; ONCOPROTEIN; PHOSPHATASE; PROTEIN; PROTEIN TYROSINE KINASE; PTEN PROTEIN, HUMAN; REPRESSOR PROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; SRC HOMOLOGY 2 DOMAIN CONTAINING, TRANSFORMING PROTEIN 1; SRC HOMOLOGY 2 DOMAIN-CONTAINING, TRANSFORMING PROTEIN 1; TRANSACTIVATOR PROTEIN; TRANSCRIPTION FACTOR; TUMOR SUPPRESSOR PROTEIN; VESICULAR TRANSPORT ADAPTOR PROTEIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL STRAIN MCF 7; CONTROLLED STUDY; DNA BINDING; ENZYME ACTIVITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; WILD TYPE; BREAST TUMOR; CELL CULTURE; FEMALE; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY; PROMOTER REGION;

MINK CELL FOCUS-FORMING VIRUS;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADAPTOR PROTEINS, VESICULAR TRANSPORT; BREAST NEOPLASMS; DNA-BINDING PROTEINS; EPIDERMAL GROWTH FACTOR; FEMALE; GROWTH SUBSTANCES; HUMANS; INSULIN; INSULIN ANTAGONISTS; MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORIC MONOESTER HYDROLASES; PHOSPHORYLATION; PROMOTER REGIONS (GENETICS); PROTEINS; PROTO-ONCOGENE PROTEIN C-ETS-2; PROTO-ONCOGENE PROTEINS; PTEN PHOSPHOHYDROLASE; RECEPTOR PROTEIN-TYROSINE KINASES; REPRESSOR PROTEINS; SIGNAL TRANSDUCTION; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS;

EID: 0037098951     PISSN: 09646906     EISSN: None     Source Type: Journal    
DOI: 10.1093/hmg/11.15.1687     Document Type: Article

References (49)

1. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast and prostate cancer
2. TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor B
3. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers
4. Expression of PTEN protein in human embryonic development
5. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome
6. Role of MMAC1 mutations in early onset breast cancer: Causative in association with Cowden's syndrome and excluded in BRCA1-negative cases
7. Novel germline mutations in the PTEN tumour suppressor gene found in women with multiple cancers
8. Will the real Cowden syndrome please stand up: Revised diagnostic criteria
9. Germline mutations in PTEN are present in Bannayan-Zonana syndrome
10. Germline and germline mosaic mutations associated with a Proteus-like syndrome of hemihypertrophy, lower limb asymmetry, arterio-venous malformations and lipomatosis
11. Association of germline mutation in the PTEN tumour suppressor gene and a subset of Proteus sand Proteus-like syndromes
12. Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation
13. PTEN mutation spectrum and genotype-phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome
14. Somatic mutations of PTEN in glioblastoma multiforme
15. Homozygous deletion of the PTEN tumor suppressor gene in a subset of prostate adenocarcinomas
16. Allelic loss of chromosome 10q23 is associated with tumor progression in breast carcinomas
17. Epigenetic PTEN silencing in malignant melanomas without PTEN mutation
18. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN
19. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger phosphoinositol 3,4,5-triphosphate
20. PTEN is inversely correlated with the cell survival factor PKB/Akt and is inactivated by diverse mechanisms in haematologic malignancies
21. PTEN, the tumor suppressor from human chromosome 10q23, is a dual specificity phosphatase
22. The lipid phosphatase activity of PTEN is critical for its tumor suppressor function
23. Inhibition of cell migration, spreading and focal adhesions by tumor supressor PTEN
24. PTEN interactions with focal adhesion kinase and suppression of the extracellular matrix-dependent phosphotidyinositol 3-kinase/Akt cell survival pathway
25. PTEN induces apoptosis and cell cycle arrest through phosphoinositol-3-kinase/Akt-dependent and independent pathways
26. Transient ectopic expression of PTEN in thyroid cancer cell lines induces cell cycle arrest and cell type-dependent cell death
27. PTEN inhibits insulin-stimulated MEK/MAPK activation and cell growth by blocking IRS-1 phosphorylation and IRS-1/Grb-2/Sos complex formation in a breast cancer model
28. Regulation of transcription by MAP kinase cascades
29. Ets transcription factors: Nuclear effectors of the Ras-MAP-kinase signaling pathway
30. Rasmediated phosphorylation of a conserved threonine residue enhances the transactivation activities of c-Ets-1 and c-Ets-2
31. Rapid phosphorylation of Ets-2 accompanies mitogen-activated protein kinase activation and the induction of heparin-binding epidermal growth factor gene expression by oncogenic Raf-1
32. Persistent activation of mitogen-activated protein kinases p42 and p44 and ets-2 phosphorylation in response to colony-stimulating factor 1/c-fms signaling
33. Conserved mechanisms of Ras regulation of evolutionary related transcription factors, Ets1 and Pointed P2
34. Activation of the ras-mitogen-activated protein kinase pathway and phosphorylation of ets-2 at position threonine 72 in human ovarian cancer cell lines
35. Role of distinct mitogen-activated protein kinase pathways and cooperation between Ets-2, ATF-2, and Jun family members in human urokinase-type plasminogen activator gene induction by interleukin-1 and tetradecanoyl phorbol acetate
36. ets-2 is a target for an akt (protein kinase B)/jun N-terminal kinase signaling pathway inmacrophages of motheaten-viable mutant mice
37. c-ets-2 protooncogene has mitogenic and oncogenic activity
38. Mitogenic signaling by colony-stimulating factor 1 and Ras is suppressed by the ets-2 DNA-binding domain and restored by myc overexpression
39. Ets-2 transdominant mutant abolishes anchorage-independent growth and macrophage colony-stimulating factor-stimulated invasion by BT-20 carcinoma cells
40. The ets gene family
41. Transforming p21ras mutants and c-Ets-2 activate the cyclin D1 promoter through distinguishable regions
42. A regulatory element within a coding exon modulates keratin 18 gene expression in transgenic mice
43. Tumor suppressor PTEN inhibits integrin- and growth factor-mediated mitogen-activated protein (MAP) kinase signaling pathway
44. PTEN coordinates G1 arrest by down regulating cyclin D1 via its protein phosphatase activity and up regulating p27 via its lipid phosphatase activity
45. Cell cycle arrest by the PTEN tumor suppressor is target cell specific and may require protein phosphatase activity
46. Signal transduction and the Ets family of transcription factors
47. PTEN suppresses breast cancer cell growth by phosphatase function-dependent G1 arrest followed by apoptosis
48. Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast
49. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers